Immune Checkpoint Inhibition Therapies

Brain cancers comprise a heterogeneous group of malignancies with significant morbidity and limited therapeutic options, including common entities such as medulloblastoma, astrocytoma and oligodendroglioma. Despite advances in surgery, radiotherapy, and chemotherapy, many patients experience disease progression and long-term neurological side-effects. Immune checkpoint inhibition has emerged as a promising strategy in oncology, yet its role in primary brain tumors remains incompletely understood.

Here, we investigate immune checkpoint expression and the therapeutic potential of dual/triple immune checkpoint blockade across brain cancers. Using primary tumors established cell lines, patient-derived xenograft organoids, and patient tissues, we assess checkpoint pathway activity and evaluate the impact of their inhibition in e.g. medulloblastoma, astrocytoma and oligodendroglioma.